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Nuclear factor-erythroid-2-related factor 2 (Nrf2) is a transcription 
factor that binds to the antioxidant response element (ARE) present in the 
promoter regions of its target genes, encoding mostly antioxidant enzymes and 
other cytoprotective proteins involved in stress response. Recent studies report 
that in contrast to its tumor suppressive functions in normal cells, Nrf2 
facilitates tumor progression in some cancer cells. However, the molecular 
mechanism underlying the oncogenic properties of Nrf2 is not yet well 
understood. Previous studies have shown that Nrf2 also regulates the expression 
of some of the pentose phosphate pathway (PPP)-related enzymes. Among 
these, phosphogluconate dehydrogenase (PGD) is of particular interest since its 
key byproducts, ribulose-5-phosphate (Ru-5-P) and the reduced form of 
nicotinamide adenine dinucleotide phosphate (NADPH) are utilized as a 
precursor for nucleotide synthesis and as a reducing agent for cellular 
antioxidant defense, respectively. The present study was intended to explore 
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the potential role of PGD, as a target protein of Nrf2, in the proliferation and 
migration of human hepatoma, HepG2 cells. Notably, Nrf2 regulates the 
transcription of PGD through direct binding to the ARE in its promoter region.  
Knockdown of Nrf2 or PGD significantly inhibited HepG2 cell proliferation 
and migration. Conversely, Nrf2 overexpression in HepG2 cells led to 
increased cell proliferation and migration, which was suppressed by silencing 
of PGD. While Nrf2 regulates PGD expression, knockdown of the gene 
encoding this enzyme downregulated the expression of Nrf2 and its target 
antioxidant enzymes, including heme oxgenase-1 and glutamate-cysteine ligase 
catalytic subunit at both transcriptional and translational levels. In particular, 
PGD knockdown upregulated Kelch-like ECH-associated protein 1 (Keap1) 
protein expression. Treatment of HepG2 cells with Ru-5-P gave rise to a 
decrease in Keap1 protein expression without influencing its mRNA transcript 
level. This was accompanied by upregulation of both Nrf2 mRNA and HO-1 
protein. Collectively, the current study shows that Nrf2 promotes hepatoma cell 
growth and migration through activation of PGD transcription and that the PGD 
product, Ru-5-P, induces Keap1 degradation to activate Nrf2 signaling. Thus, 
there seems to exist a positive-feedback loop between Nrf2 and PGD which is 
exploited by hepatoma cells for their survival. 
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Nuclear factor-erythroid-2-related factor 2 (Nrf2) is a transcription 
factor widely known to be involved in the cellular defense against oxidative 
stress by controlling the expression of genes responsible for antioxidant and 
stress responses1,2. Due to this, Nrf2 has been considered as a protective protein 
which became one of the prime targets for chemoprevention3. However, recent 
studies show that cancer cells also harness Nrf2 to facilitate tumor growth and 
promote chemoresistance4. Numerous cancer types were found to have 
mutations in Nrf2, or its inhibitor Kelch-like ECH-associated protein 1 (Keap1), 
which resulted in a constitutively high expression of Nrf2 in these cells5,6. 
Furthermore, Nrf2 was found to stimulate proliferation and invasiveness of 
various cancer cells7–9. Yet, the molecular mechanisms by which Nrf2 promotes 
cancer plasticity have not yet been fully elucidated. Nrf2 activates its target 
genes by binding to the antioxidant response element (ARE) present 5’-
upstream of their promoter region10. AREs, also known as electrophile response 
element (EpRE), has a core sequence of 5′-TGAG/CNNNGC-3′11. In an 
oligonucleotide microarray performed to determine Nrf2-regulated genes, a 
series of metabolic enzymes were identified as Nrf2 products12.  
Metabolic reprograming is one of the ten hallmarks of cancer identified 
in Hanahan and Weinberg’s review paper published in 201113. A growing body 
of evidence shows that metabolic reprogramming is necessary in order to 
support cancer cell growth and proliferation14–16. The Warburg effect describes 
the phenomenon in which cancer cells rely on aerobic glycolysis, rather than 
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the more efficient mitochondrial oxidative phosphorylation to generate the 
energy needed for cellular processes17. In addition, this shift provides the cells 
with important macromolecular precursors needed to support cell proliferation 
and tumor growth18. Also, rather than just an indirect phenomenon, it is directed 
by oncogenes in order to support anabolic growth in cancer cells19.  
Phosphogluconate dehydrogenase (PGD) is the third enzyme in the 
pentose phosphate pathway (PPP) which converts 6-phosphogluconate to 
ribulose-5-phosphate (Ru-5-P) through oxidative decarboxylation. During this 
process, one molecule of the reduced form of nicotinamide adenine 
dinucleotide phosphate (NADPH) is also produced. NADPH is essential for 
both cellular defence against oxidative stress and for reductive biosynthesis, 
such as lipogenesis20. Ru-5-P can be converted by ribose-5-phosphate 
isomerase to ribose-5-phosphate which provides the backbone for nucleotides21. 
Increased activity and expression of PGD have been reported in several cancers 
including lung22, thyroid23, and cervical intraepithelial neoplasia24. Suppression 
of PGD was found to attenuate cancer cell proliferation through reduction of 
lipogenesis and RNA biosynthesis25. Likewise, PGD knockdown suppresses 
tumor growth by inducing senescence in lung cancer cells26. Additionally, PGD 
was found to be necessary for c-Met phosphorylation for the promotion of 
tumor cell invasiveness in lung cancer cells22. However, the mechanisms 
underlying oncogenic functions of PGD as a downstream target gene of Nrf2 
remain elusive.  
In this study, the role of PGD in cancer cell proliferation and migration 
induced by Nrf2 were investigated in human hepatoma HepG2 cells. Nrf2 
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promoted PGD transcription by directly binding to the ARE in the promoter 
region of PGD. Furthermore, PGD was found to be a crucial downstream target 
gene in the Nrf2-mediated proliferation and migration. Notably, PGD 
comprises a positive-feedback loop with Nrf2. PGD, through its byproduct Ru-
5-P, was found to induce Keap1 degradation resulting in an upregulation of 




















Materials and Methods 
 
Materials 
Dulbecco's modified Eagle's medium (DMEM) and Antibiotic-Antimycotic 
(100X) were products of GIBCO BRL (Grand Island, NY, USA). Fetal bovine 
serum (FBS) was purchased from GenDEPOT (Barker, TX, USA). Primary 
antibodies against Nrf2, PGD, lamin B, Keap1, and α-tubulin were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The primary antibody 
for HO-1 was bought from Enzo Life Sciences (Farmingdale, NY, USA). The 
primary antibodies for actin and GCLC were obtained from AbClon Inc (Seoul, 
South Korea). Antibody against p62 was purchased from Abcam (Cambridge, 
MA, USA). The primary anti-rabbit IgG, HRP-linked antibody was bought 
from Cell Signalling Technology (Beverly, MA, USA). TRIzol®, SYBR®safe 
DNA gel stain, Lipofectamine® RNAiMAX, and Lipofectamine® 2000 were 
provided by Invitrogen (Carlsbad, CA, USA). Polyvinylidene difluoride 
(PVDF) membranes were supplied by Gelman Laboratory (Ann Arbor, MI, 
USA). Protease inhibitor cocktail tablets were provided by Boehringer 
Mannheimm (Mannheimm, Germany). The protein assay dye (Bradford) 
reagent was supplied by Bio-Rad Laboratories (Hercules, CA, USA). 
Actinomycin D and Ru-5-P were purchased from Sigma Chemical Co. (St. 
Louis, MO, USA). The bicinchonic acid (BCA) protein assay reagent was 
obtained from Pierce Biotechnology (Rockford, IL, USA). All other chemicals 




HepG2 cells were obtained from American Type Culture Collection (Manassas, 
VA, USA) and cultured in DMEM medium supplemented with 10% v/v FBS 
and 100 units/mL antibiotic-antimycotic at 37°C in an incubator with 
humidified atmosphere of 95% air/5% CO2. 
 
Immunocytochemical Analysis 
HepG2 cells transfected with either siControl or siPGD were plated on 8-well 
chamber slides at a density of 2 x 104 per well. After fixation with 4% 
formaldehyde for 15 min at 37oC, cells were rinsed with PBST (Phosphate-
buffer saline containing 0.1% Tween-20) and treated with 0.1% Triton X-100 
in PBS for 5 min. Then, the cells were washed and blocked with 0.05% Triton 
X-100 in PBS containing 5% bovine serum albumin (BSA) at room temperature 
for 1 h. The cells were then washed with PBST and then incubated with diluted 
(1:200) primary antibody overnight at 4oC. After washing with PBST, samples 
were incubated with FITC-conjugated anti-rabbit secondary antibody in PBST 
(1:1000) containing 5% BSA at room temperature for 1 h. Samples were 
washed with PBST and stained with DAPI (4',6-diamidino-2-phenylindole) in 
PBS (1:3000) for 15 min. The samples were then washed with PBST and 







Two-well Culture-Inserts (Ibidi®) were attached to 12-well plates. HepG2 cells 
transfected with the appropriate reagent were seeded at a density of 2.5 x 104 
cells on each well of the Culture-Insert. After 24 h, the silicon inserts were 
removed and photographed under the microscope. The cells were again 
photographed after 48 h to assess the closure of the wound gap.  
 
Transfection  
siRNA transient transfection 
HepG2 cells were reverse transfected with siRNA. The following siRNAs were 
used for transfection: human negative-siRNA (5’-
CCUCGUGCCGUUCCAUCAGGUAGUU-3’), siNrf2 (5’-
AAGAGUAUGAGCUGGAAAAACTT-3’, Invitrogen), siPGD#1 (5’-
CUCUUCGGUUCUGCUCUGU-3’, Bioneer), and siPGD#2 (5’-
CUCACACCUAUGAACUCUU(dTdT)-3’, Bioneer).  siRNA was diluted in 
1mL Opti-MEM and vortexed to mix. Lipofectamine® RNAiMAX reagent was 
then added to the mixture and the mixture was incubated for at least 20 min 
prior to addition to the freshly seeded cells in media without antibiotics and 
FBS. At 24 h after transfection, the media was changed to full media (with 10% 
FBS and 1% antibiotic-antimycotic). This is then incubated for another 48 h, 






HepG2 cells were transfected with pcDNA 3.1 plasmid carrying cDNA for Nrf2 
and a Myc tag (Plasmid #21555; Addgene; Cambridge, UK) using 
Lipofectamine®2000 reagent. The transfection was done according to the 
manufacturer’s instructions. An ‘empty’ vector, pcDNA 3.1 plasmid, was 
considered as mock or control.  
 
Chromatin Immunoprecipitation (ChIP) Assay  
For ChIP assays, cells were washed with PBS and crosslinked with a 1% 
formaldehyde solution for 30 min at room temperature (25 °C). The 
crosslinking reaction was stopped by the addition of glycine to 125mM final 
concentration. Cell lysates were sonicated to generate DNA fragments with the 
average size of 300 to 600 base pairs. This was followed by 
immunoprecipitation with indicated antibodies, which were bound to Protein 
Agarose A/G (Santa Cruz, CA, USA) by an overnight incubation prior to use. 
Bound DNA fragments were eluted and purified using the Biomedic® Plasmid 
DNA Miniprep Kit (Seoul, Korea). The collected DNA was then amplified by 








Western blot analysis 
Cells were first gently washed with cold PBS. Lysis buffer was then added to 
the plate and the cells were scraped and collected in a tube. The collected cells 
were incubated for 20 min at 4°C with continuous vortexing. This was then 
centrifuged at 12,000 rpm for 30 min at 4°C. The supernatant was collected as 
whole cell lysate. For obtaining the cytosolic and nuclear extracts, buffer A and 
buffer C were used respectively. Pellets were resuspended in hypotonic buffer 
A [10mM HEPES (pH 7.9), 1.5mM MgCl2, 10mM KCl, 0.5mM DTT and 
0.2mM PMSF] for 15 min on ice. After that 0.1% Nonidet P-40 was added and 
the mixture was incubated for less than 5 min. It was then centrifuged at 12,000 
rpm for 5 min at 4oC. The supernatant containing the cytosolic fraction was 
recovered and the pellets were rinsed twice with hypotonic buffer A and 
resuspended again in the hypertonic buffer C [20mM HEPES (pH 7.9), 1.5mM 
MgCl2, 420mM NaCl, 0.5mM DTT, 0.2mM PMSF, 0.2mM EDTA and 20% 
glycerol]. After incubation for 1 h on ice, the mixture was centrifuged at 12,000 
rpm for 15 min at 4oC. The supernatant was collected as nuclear extract. The 
protein concentration of whole cell lysates was determined using the BCA 
protein assay kit. Protein samples from whole cell lysates were mixed with 
sodium dodecyl sulfate (SDS) loading dye and boiled at 99°C for 10 minutes. 
Protein samples were electrophoresed on SDS-polyacrylamide gel and 
transferred to PVDF membranes. The blots were then blocked with 5% fat-free 
dry milk in PBST buffer for 1 hour at room temperature. The membranes were 
then incubated with primary antibodies diluted in PBST at 4°C overnight. After 
incubation, the membranes were washed, followed by incubation with 1:5000 
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dilution of the corresponding horseradish peroxidase (HRP)-conjugated 
secondary antibodies (rabbit or mouse; Zymed Laboratories) in 2% fat-free dry 
milk in PBST for 1 h, followed again by washing with PBST. Protein bands 
were visualized with the ECL substrate detection reagent using the LAS-4000 
image reader (Fuji film).  
 
Polymerase Chain Reaction (PCR) 
Total RNA was isolated from HepG2 cells using TRIzol® (Invitrogen) 
according to the manufacturer’s protocol. One microgram of the extracted RNA 
for each sample was reverse transcribed to complementary DNA with MLV 
reverse transcriptase at 42°C for 50 min and 72°C for 15 min. One µL of cDNA 
was used for further amplification in sequential reactions using Solg™ 2X Taq 
PCR Smart mix 1 (SolGent; Seoul, Korea). The mRNA expressions of target 
genes were checked. The primer sequences and conditions used for each PCR 
reaction are listed in Table 1. 
 
Colony Formation Assay  
The cells were transfected with the indicated expression vectors or siRNAs in 
a 60 mm plate as described above. After 72 h of transfection, the cells were 
washed, counted and plated at a density of 500 cells per well in a 6-well plate. 
Cells were further cultured for 10 days in standard conditions. The plates were 
washed with PBS, fixed with chilled methanol for 10 min, and stained with 0.1% 
crystal violet solution. Plates were imaged by LAS-4000 image reader (Fuji 
film) and colonies having more than 50 cells were counted.  
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Table 1. List of primer sequences used 
 







Gene Forward Reverse   
PCR   
NRF2 
TTC AAA GCG 
TCC GAA CTC 
CA 
AAT GTC TGC 
GCC AAA AGC 
TG 
52 25 
Hmox1 CTC CCA GGG CCA TGA ACT TT 
GAC AGC TGC 
CAC ATT AGG GT 57 25 
PGD GCT CTT CGG TTC TGC TCT GT 
CCA GTT CCC 
ACT TTT GCA GC 56 25 
Keap1 
CAG AGG TGG 
TGG TGT TGC 
TTA 
AGC TCG TTC 




TGA AGG GAC 
ACC AGG ACA 
GCC 
GCA GRG RGA 




ACC ACA GTC 
CAT GCC ATC 
AC 
TCC ACC ACC 
CTG TTG CTG TA 57 24 
ChIP Assay   
PGD-
ARE 
CCC CCT CTA 
ACA GGA AGG 
GT 
ACC ACT TTT 




Cell Viability Assay/MTT Assay 
Transfected cells incubated for 72 hours were trypsinized and seeded at a 
density of 3.5 x 103 cells per well in a 96-well plate. After 48 h of incubation, 
the media was changed with a 0.5mg/mL of thiazolyl blue tetrazolinium 
bromide (Sigma, St. Loius, MO, USA) in DMEM (MTT). The cells were 
incubated with MTT for 3 h. MTT was then removed, and DMSO was added 
to solubilize the formazan crystals formed. The absorbance per well was 
measured at 570 nm using a micro-plate reader (Bio-Rad Laboratories; 




Results were expressed as the means ± SEM of at least three independent 
experiments. The statistical significance of the difference between two groups 
was evaluated using Student’s t test. Analysis was performed using IBM SPSS 
Statistics (Version 23). Statistical significance was accepted at p < 0.05, unless 





















Nrf2 directly regulates PGD transcription in HepG2 cells 
Nrf2 has been shown to regulate the expression of metabolic enzymes in various 
cancer cell lines7,12. Knockdown of Nrf2 with siRNA resulted in the inhibition 
of mRNA and protein expression of PGD (Fig. 1A and 1B). The efficiency of 
Nrf2 knockdown was monitored by measuring HO-1 protein levels, a well-
known target of Nrf227. Upon activation, the heterodimer Nrf2 bound to a small 
Maf protein interacts with the ARE in the regulatory region of its target 
genes28,29. Nrf2 has been found to directly bind to the ARE-region in PGD in 
A549 cells7. To confirm Nrf2 interaction with the ARE consensus sequence in 
the PGD regulatory region in HepG2 cells, a ChIP assay was performed (Fig. 
1C). The results show that Nrf2 induces expression of PGD by directly binding 
to the ARE found in its promoter region.  
To explore whether Nrf2 is associated with the stability of PGD mRNA, 
HepG2 cells were treated with Actinomycin D (10 µg/mL) to inhibit mRNA 
synthesis. However, the degradation of PGD mRNA did not significantly differ 
between siControl and siNrf2 transfected cells, suggesting that Nrf2 is unlikely 
to be involved in the stabilization of the PGD mRNA (Fig. 1D). 
 
Nrf2 promotes cell proliferation and invasion of HepG2 cells 
Fundamental marks of malignant cancer are the presence of proliferative and 
invasive phenotypes30. Nrf2 was silenced through transfection of an siRNA 
targeting Nrf2, while overexpression was achieved by transfection of the cell 
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with pcDNA 3.1-Nrf2-Myc plasmid. Previous studies showed that Nrf2 
promotes proliferation and survival in several cell types including cancer 
cells7,31,32. To validate this in HepG2 cells, several tests including the MTT 
Assay and the clonogenic assay were performed. The silencing of Nrf2 by 
siNrf2 transfection attenuated cell proliferation and survival (Fig. 2A and 2B) 
while Nrf2 overexpression provoked an opposite effect. Furthermore, HepG2 
cells transfected with siNrf2 showed reduced migration at 48 h (Fig. 2C). 
Conversely, opposite effects were observed in the group transfected with 
pcDNA 3.1-Nrf2-Myc plasmid compared to the group transfected with an 
empty vector (Fig 2D, E and F).  
 
PGD is important for proliferation and migration in HepG2 cells 
Rapid proliferation of cancer cells requires not only ATP but also building 
blocks necessary for the synthesis of lipids, nucleotides and amino acids14. The 
byproducts of PGD are NADPH, used for biosynthesis of many important 
cellular components, and Ru-5-P, a precursor in nucleic acid biosynthesis25. 
HepG2 cells were transfected with siControl or siPGD and cell proliferation 
and survival were evaluated using the MTT assay (Fig 3A) and the clonogenic 
assay (Fig. 3B), while migration was assessed by the use of wound-healing 
migration assay (Fig. 3C). PGD knockdown resulted in a decreased 
proliferation and migration of HepG2 cells. In addition, PGD was 
overexpressed in HepG2 cells by transfection of a PGD expression plasmid and 
proliferation was measured using the MTT assay (Fig. 3D) and the clonogenic 
assay (Fig. 3E). Overexpression of PGD resulted to an increased proliferation  
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Nrf2 regulates cell proliferation and migration through PGD upregulation 
Cells transfected with either pcDNA 3.1 (Mock) or pcDNA 3.1-Nrf2-Myc 
plasmid (Nrf2 plasmid) were co-transfected with either siControl or siPGD (Fig. 
4). Nrf2 plasmid-siControl co-transfected cells had an increased proliferation 
compared to the Mock-siControl co-transfected cells. However, this was 
inhibited by the knockdown of PGD in the Nrf2 plasmid transfected cells (Nrf2 
plasmid-siPGD) (Fig. 4A). Given that the increase in cell proliferation due to 
Nrf2 over-expression was hindered by silencing of PGD, this finding suggests 
that PGD is required by Nrf2 in the promotion of cell proliferation of HepG2 
cells. Similar results were observed when these groups were subjected to a 
wound healing assay. The increased migratory capability observed in Nrf2 
plasmid-siControl was attenuated in Nrf2 plasmid-siPGD cells which suggests 
that Nrf2-mediated migration also requires PGD (Fig. 4B).  
 
PGD regulates Nrf2 through a positive-feedback loop 
A previous study provided evidence that glucose-6-phosphate dehydrogenase 
(G6PD), the first enzyme in the PPP, and NADPH are important in the 
expression of Nrf2-initiated antioxidant proteins, HO-1 and glutathione 
reductase33. Since PGD is part of the PPP, I first examined its effect on the 
transcription and translation of Nrf2 target genes. Well recognized target genes 
of Nrf2 are antioxidant and phase II enzymes which include HO-134 and the 
catalytic subunit of GCLC35. Knockdown of PGD downregulated their mRNA 
(Hmox1 and GCLC) and protein (HO-1 and GCLC) expressions (Fig. 5A and 
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5B). Surprisingly, the mRNA level of Nrf2 was also downregulated in HepG2 
cells transfected with siPGD (Fig. 5C). In addition, the expression of Nrf2 in 
Nrf2-overexpressing HepG2 cells was attenuated after siPGD co-transfection 
compared to the control (Fig. 5D). Furthermore, subcellular fractionation (Fig. 
5E) and immunocytochemistry (Fig.  5F) showed that knockdown of PGD 
decreased the nuclear localization of Nrf2. 
 
PGD promotes the degradation of Keap1, a negative regulator of Nrf2 
Keap1 is a negative regulator of Nrf236. It interacts with the N-terminal Neh2 
domain of Nrf2 to facilitate its proteolytic degradation37. PGD silencing 
upregulated Keap1 protein (Fig. 6A), but not mRNA (Fig. 6B) levels. This 
suggests that PGD promotes the degradation of Keap1 protein primarily via 
post-transcriptional mechanisms. Previous studies have shown degradation of 
Keap1 through p62-dependent autophagy38. Of note, knockdown of PGD 
decreased p62 protein levels (Fig. 6C). This suggests that p62-dependent 
degradation of Keap1 may be one mechanism underlying the positive-feedback 
loop between PGD and Nrf2. 
 
Ru-5-P increases mRNA expression of Nrf2 and upregulates HO-1 protein 
levels 
PGD converts 6-phosphogluconate to Ru-5-P which then enters the non-
oxidative arm of the PPP and proceeds to purine biosynthesis39. To determine 
whether this metabolite affects the Nrf2 regulatory network, HepG2 cells were 
treated with increasing doses (400, 600, and 800 µM) of Ru-5-P for 24 h. Ru-
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5-P treatment increased Nrf2 mRNA levels in a dose-dependent manner (Fig. 
7A). As an indicator of Nrf2 activity, HO-1 protein levels were measured by 
Western blot analysis. As seen in Fig. 7B, there was a dose-dependent 
upregulation of HO-1 following Ru-5-P treatment. Moreover, the concurrent 
downregulation of Keap1 protein (Fig. 7C) supports the notion that the positive 









































































Figure 1. Nrf2 regulates the transcription of PGD by binding to the ARE 
in its promoter region. HepG2 cells were transfected with either a non-
targeting siRNA or siNrf2 and incubated for 72 h. (A) The expression of PGD 
was determined by PCR. Relative mRNA levels were normalized to GAPDH. 
(B) Total cell lysates were evaluated by Western blot analysis. Band intensities 
were normalized to actin.  (C) ChIP assay was performed on Widl-type HepG2 
cells to detect the binding of Nrf2 to the ARE in the promoter region of PGD. 
Protein-DNA complexes were stabilized by crosslinking. Nrf2 was 
immunoprecipitated from the lysate. Reverse crosslinking was performed and 
DNA was extracted and purified. Samples were amplified through PCR. Band 
intensities were normalized to GAPDH. (D) Transfected cells were treated with 
actinomycin D (10 µg/mL) for 0, 0.5, 1, 2, 4, and 8 h. Mean band intensities 
normalized to GAPDH was divided by the 0 h control. The mean from each 
time point was plotted vs. time. For all panels, each bar shows the mean of three 
independent experiments ± SEM. The p-values were determined by 


















































Figure 2. Nrf2 mediates proliferation and migration in HepG2 cells.  (A to 
C) HepG2 cells were transfected with either a non-targeting siRNA or siNrf2 
(A) After 48 h of incubation, cells were seeded in a 96-well plate. Cell viability 
was measured by the MTT assay 48 h after seeding. (B) After 48 h of incubation, 
cells were seeded in a 6-well plate. Formed colonies were counted after 10 days 
of incubation. (C) Cells were seeded into the two wells of an insert. After 24 h, 
the insert was removed and the cells were incubated for 48 h more. The wound 
gap was measured under a light microscope. (D to F) HepG2 cells transfected 
with pcDNA 3.1 (Control) or pcDNA 3.1-Nrf2-Myc (Nrf2-expressing plasmid). 
(D) After 24 h of incubation, cells were seeded in a 96-well plate. Cell viability 
was measured by the MTT assay 48 h after seeding. (E) After 24 h of incubation, 
cells were seeded in a 6-well plate. Formed colonies were counted after 
incubation for 10 days. (F) Cells were seeded into the two wells of an insert. 
After 24 h, the insert was removed and the cells were incubated for 48 h more. 
The gap was measured under a light microscope. For all panels, each bar shows 
the mean of three independent experiments ± SEM. The p-values were 
determined by independent t-test (∗, 0.05 > p > 0.01; ∗∗ , 0.01 > p > 0.001; ∗∗∗ , 




































Figure 3. PGD is involved in HepG2 cell proliferation and migration.  (A 
to C) HepG2 cells were transfected with either a non-targeting siRNA or siPGD. 
(A) After 48 h of incubation, cells were seeded in a 96-well plate. Cell viability 
was measured by the MTT assay 48 h after seeding. (B) After 48 h of incubation, 
cells were seeded in a 6-well plate. Colonies were counted after 10 days of 
incubation. (C) Cells were seeded into the two wells of an insert. After 24 h, 
the insert was removed and the cells were incubated for 48 h more. The wound 
gap was measured under a microscope. (D to E) HepG2 cells transfected with 
pcDNA 3.1 (Control) or PGD plasmid (PGD-expressing plasmid). (D) After 24 
h of incubation, cells were seeded in a 96-well plate. Cell viability was 
measured by the MTT assay 24 h after seeding. (E) After 24 h of incubation, 
cells were seeded in a 6-well plate. Formed colonies were counted after 
incubation for 10 days. For all panels, each bar shows the mean of three 
independent experiments ± SEM. The p-values were determined by 
independent t-test (∗, 0.05 > p > 0.01; ∗∗ , 0.01 > p > 0.001; ∗∗∗ , 0.001 > p vs. 






































Figure 4. PGD is involved in Nrf2-mediated HepG2 cell proliferation and 
migration. HepG2 cells were transfected with either a non-targeting siRNA or 
siPGD and incubated for 24 h. Each group was then subsequently co-
transfected with either pcDNA 3.1 (Control) or pcDNA 3.1-Nrf2-Myc (Nrf2-
expressing plasmid). (A) After 48 h of incubation, cells were seeded in a 6-well 
plate. Formed colonies were counted after 10 days of incubation. (B) Cells were 
seeded into the two wells of an insert. After 24 h, the insert was removed and 
the cells were incubated for 48 h more. The wound gap was measured under a 
microscope. For all panels, each bar shows the mean of three independent 
experiments ± SEM. The p-values were determined by independent t-test (∗, 
0.05 > p > 0.01; ∗∗ , 0.01 > p > 0.001; ∗∗∗ , 0.001 > p vs. control). Scale bar 














































Figure 5. PGD regulates Nrf2 expression through a positive-feedback loop.  
HepG2 cells were transfected with either a non-targeting siRNA or siPGD 
siRNA sequences and incubated for 72 h. (A) mRNA levels of Nrf2 target genes 
were evaluated by RT-PCR. Band intensities were normalized to GAPDH. (B) 
Protein levels of Nrf2 target genes were evaluated by RT-PCR. Band intensities 
were normalized to actin. (C) The mRNA levels of Nrf2 were determined by 
RT-PCR. Obtained bands were normalized to GAPDH. (E) Cells transfected 
with pcDNA 3.1-Nrf2-Myc were co-transfected with either a non-targeting 
siRNA or siPGD. Total lysates were evaluated by Western blot analysis. Band 
intensities were normalized to actin. (E) siControl or siPGD transfected cells 
were subjected to subcellular fractionation and analyzed by Western blot 
analysis. (F) Cells were fixed and the localization of Nrf2 was visualized by 
immunofluorescence staining. For all panels, each bar shows the mean of three 
independent experiments ± SEM. The p-values were determined by 






















Figure 6. PGD promotes the protein degradation of Keap1.  (A to C) HepG2 
cells were transfected with either a non-targeting siRNA or siPGD. (A) The 
expression of Keap1 was determined by PCR. Relative mRNA levels were 
normalized to GAPDH. (B to C) Total cell lysates were evaluated by Western 
blot analysis. (B) The band intensities of Keap1 were normalized to actin. (C) 
The protein level of p62 was determined by Western blot analysis and values 
were normalized to actin. For all panels, each bar shows the mean of three 
independent experiments ± SEM. The p-values were determined by 
independent t-test (∗, 0.05 > p > 0.01; ∗∗ , 0.01 > p > 0.001; ∗∗∗ , 0.001 > p vs. 
control). ns, not significant.  
 
  




Figure 7. Ru-5-P regulates the positive feedback loop between PGD and 
Nrf2. HepG2 cells were treated with 0, 400, 600, and 800 µM of Ru-5-P for 24 
h. (A) The mRNA level of Nrf2 was determined by PCR. Relative mRNA levels 
were normalized to GAPDH. (B to C) Total cell lysates were evaluated by 
Western blot analysis. (B) The band intensities of HO-1 and (C) Keap1 were 
normalized to actin.  For all panels, each bar shows the mean of three 
independent experiments ± SEM. The p-values were determined by 












Figure 8. A schematic representation of the mechanism underlying the 
proposed positive-feedback loop between Nrf2 and PGD. Nrf2 binds to the 
ARE consensus sequence present in the PGD regulatory region, thereby 
promoting its transcription in HepG2 cells. The increased PGD expression leads 
to hepatoma cell proliferation and migration. Moreover, the increase in the PGD 
product Ru-5-P, induces the degradation of Keap1 to create a positive feedback 














Two decades have passed since the function of Nrf2 as a regulator of 
antioxidant response and hence, a protector from environmental insults and 
disease development was discovered40. Damage to DNA, proteins, or lipids due 
to oxidative stress has been linked to inflammation and cancer, among other 
diseases41. Nrf2-knockout mice were found to be more susceptible to 
environmental carcinogens42,43. Furthermore, sensitivity to the chemoprotective 
effects of various phytochemicals was diminished in nrf2-knockout mice44,45. 
On the other hand, mutations to either Nrf2 or its regulatory proteins were found 
to lead to its aberrant overactivation in several cancers such as, epithelial,  
squamous cell46, renal47, lung48, breast, prostate49 and liver cancer50. Nrf2 
provides cancer cells with ample reducing power to maintain ROS at levels to 
promote their growth and survival51. Evidence supporting the effect of Nrf2, 
either protective52–54 or harmful55,56, are still being published in the recent years. 
Thus, there is a need to conduct additional research in order to more accurately 
predict the function of Nrf2 in a defined disease state. In order to better 
understand the biological role of a transcription factor, it is important to identify 
and characterize its target genes57. I showed through ChIP assay that Nrf2 
regulates PGD through binding to the ARE in the regulatory region of PGD in 
HepG2 cells. This finding is consistent with the result of a previous study done 
with lung cancer cells7. 
Increasing evidence shows that cancer is also a metabolic disease58. 
Metabolic reprogramming in cancer cells supports bioenergetics and the 
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macromolecular synthesis needed in their proliferation which accompany 
activation of distinct signal transduction pathways and transcriptional network 
reorganization59. The high catalytic activity of PGD has been associated with 
poor relapse-free survival times in breast cancer60. Elevated PGD expression 
levels also correlate with an advancing stage of lung carcinoma. Notably, PGD 
was found to be required in the phosphorylation of c-Met to promote migration 
of lung carcinoma cells22. Previous studies have demonstrated that the 
inhibition of cancer cell proliferation upon PGD knockdown is mediated 
through a senescence-associated mechanism22,26. Moreover, it has been 
suggested that inhibition of proliferation upon PGD knockdown may be due to 
accumulated glucose metabolites. In one study, it was shown that the 
suppression of cell proliferation due to PGD silencing was recovered upon 
silencing G6PD26. 
Nrf2 target genes have been shown to partake in cell growth and 
tumorigenesis. HO-1, one of the most well-known targets of Nrf2, was shown 
to be involved in the metastasis61, invasion62, and inhibition of apoptosis63 in 
various cancer types. Similarly, NQO1 overexpression, which is found to be 
elevated in several solid tumors64,65, also plays a role in the growth and 
chemoresistance of tumors66–68. In addition, higher protein levels of GCLC were 
found in colorectal tumor tissue compared to adjacent normal tissue69, and this 
has been implicated in the development of tamoxifen-resistant breast cancer70. 
Unlike these Nrf2-regulated antioxidant enzymes, there are relatively few 
reports describing the signals related to PGD as a modulator the tumorigenic 
processes mediated by Nrf2. The present study provides convincing evidence 
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supporting the involvement of PGD in Nrf2-mediated proliferation and 
migration in HepG2 cells. Furthermore, this study proposes a positive-feedback 
loop between Nrf2 and PGD as the underlying mechanism regulating these 
processes. 
In normal conditions, Keap1, a cysteine-rich cytoskeleton binding protein, 
binds to Nrf2 in the cytoplasm inhibiting its translocation to the nucleus71. It 
also facilitates the degradation of Nrf2 by serving as an adaptor between Nrf2 
and the Cullin3-based E3-ligase ubiquitylation complex72. In hepatocytes, one 
mechanism of Keap1 degradation involves p62-dependent autophagy38. The 
DPSTGE domain in p62 interacts with arginine residues at the Kelch domain 
of Keap1, the same domain of Keap1 that interacts with Nrf273. p62 then binds 
ubiquitin and LC3 and acts as a substrate for selective autophagy74. This present 
study has shown that silencing PGD, increases Keap1 and decreases p62 
protein levels. These results suggest that the positive feedback loop between 
Nrf2 and PGD is facilitated by the destabilization of Keap1 protein. However, 
the involvement of p62-dependent autophagic degradation of Keap1 needs 
further confirmation.  
Oncometabolites are endogenous metabolites whose abnormal 
accumulation contributes to the growth and metastasis of tumors75. Several 
oncometabolites have already been identified and many of these play a role in 
the control of cell division processes76–78. PGD activity produces Ru-5-P and 
NADPH as byproducts. NADPH is vital for the protection of cells from ROS-
induced oxidative damage by providing a reducing power 20. However, the 
magnitude of the effect of PGD in the regulation of overall NADPH production 
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in cancer cells is still in question. It has been reported that although PGD 
knockdown increases ROS levels in the cell, inhibition of PGD does not alter 
the steady-state level of NADPH26. On the other hand, Ru-5-P is a precursor for 
nucleotide synthesis. Interestingly, Ru-5-P was found to inhibit AMPK 
activation and hence, activate lipogenesis through disruption of the active 
LKB1 complex79. The results of this study indicate that Ru-5-P plays a role in 
the positive feedback loop between PGD and Nrf2. The results also demonstrate 
that Ru-5-P may be a potential oncometabolite in hepatocellular carcinoma.   
This study demonstrates, for the first time, the existence of a positive-
feedback loop between PGD and Nrf2. In leukemia cells, targeting PGD was 
proven to be selective and nontoxic to normal cells25. Hence, the positive 
feedback loop between PGD and Nrf2 opens an exciting possibility of 
attenuating Nrf2 signalling by targeting PGD in cancer cells, especially for 
those which exhibit chemoresistance due to Nrf2 overactivation. Considering 
that the role of Nrf2 in cytoprotection is still debatable, targeting PGD may be 
a good alternative strategy and should be examined in future studies. 
In summary, Nrf2 regulates the expression of PGD by directly binding to 
the ARE in its regulatory region. Moreover, the regulation of PGD by Nrf2 
plays an important role in Nrf2-mediated tumor plasticity through stimulation 
of cell proliferation and migration. Notably, the PGD product Ru-5-P, is 
suggested to induce these oncogenic effects by inducing activation of Nrf2, and 
subsequently upregulation of its target genes, in a positive-feedback loop. 
Taken together, these results suggest the possibility of PGD as a potential target 
in inhibiting tumor growth in hepatocellular carcinoma.  However, in order to 
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utilize this pathway for cancer treatment, further mechanistic and clinical 
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Nrf2 를 통한 HepG2 인간 간종양 세포의 증식과 전이에서 
포스포글루콘산 탈수소효소의 역할 규명 
 
Nuclear factor-erythroid-2-related factor 2 (Nrf2)는 항산화 
효소 및 기타 스트레스 반응과 연관된 다른 세포 보호 단백질을 
암호화하는 유전자의 프로모터 영역에 있는 antioxidant response 
element (ARE) 와 주로 결합하는 전사인자이다. 정상 세포에서 Nrf2 는 
암화 과정을 억제하지만, 일부 암  세포에서는 암화 과정을 촉진하는 
것으로 알려졌다. 하지만, 아직까지 Nrf2 의 종양 생성 능력을 가름하는 
분자적 메커니즘은 정확히 알려지지 않았다. 선행 연구를 통해 우리는 
Nrf2 가 5 탄당 인산화경로 (Pentose phosphate pathway) 관련 효소의 
발현을 조절하는 것을 확인하였다. 포스포글루콘산 탈수소효소 
(phosphogluconate dehydrogenase, PGD)는 뉴클레오티드 합성의 
전구체인 리블로스 -5-인산 (Ru-5-P)과 세포항산화방어에 필요한 
NADPH 를 핵심 부산물로 생성한다. 
본 연구자 Nrf2 의 표적 유전자인 PGD 가 인체 간암 HepG2 
세포의 증식과 전이에 미치는 역할을 규명하고자 하였다. Nrf2 는 
PGD 의 ARE 영역에 직접 결합함으로써 PGD 의 전사를 조절하였다. 
Nrf2 혹은 PGD 의 유전자를 저해하였을 때 HepG2 세포의 증식과 
침투성이 억제되었으나, Nrf2 의 과발현은 PGD 의 유전자를 
silencing 함으로써 억제되었던 HepG2 세포의 증식과 전이능을 
복원시켰다. PGD 유전자 억제는 Nrf2 와 그의 하위 유전자인 heme 
oxgenase-1, NAD(P)H quinine oxidoreductase 1 과 glutamate-
cysteine ligase catalytic subunit 의 mRNA 및 단백질 발현을 동시에 
감소시켰다. 또한, PGD 유전자를 억제했을 때 Nrf2 의 핵내 이동도 
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감소하였다. 결론적으로, 본 연구에서는 Nrf2 는 PGD 의 발현을 
증가시켜 간종양 세포의 증식과 전이를 촉진시키며, PGD 는 자신의 
유전자 발현을 조절하는 Nrf2 신호 전달 체계를 활성화함을 확인하였다. 
이는 Nrf2 와 PGD 사이에 양성 되먹임 고리(positive feeback loop)가 
존재함을 시사하며, 간암 세포는 생존을 위해 이 메커니즘을 이용하는 
것으로 사료된다. 
 
주요어 : Nuclear factor-erythroid-2-related factor 2 (Nrf2), 
포스포글루콘산 탈수소효소 (Phosphogluconate dehydrogenase, 
PGD), 항산화 반응 효소 (Antioxidant response element), 5 탄당 
인산화경로 (Pentose phosphate pathway, PPP), Ribulose-5-
phosphate (Ru-5-P), 인간 간종양 HepG2 세포 
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